Salesforce.com to B...
Health Care: Drugs
Catalyst Pharmaceutical Partners Inc. (CPRX: NASDAQ)
$0.57 0.00 | 0.04%
06/04/12 - 03:54 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 0.00 | 488.96K | 0.00 | 0.00 |
| Cost of Sales | -42.84K | -25.74K | -30.23K | -33.00K |
| Gross Operating Profit | 42.84K | 514.70K | 30.23K | 33.00K |
| Selling, General, and Administrative Expenses | 2.70M | 2.21M | 2.18M | 2.18M |
| Research & Development | 3.38M | 2.31M | 5.10M | 8.71M |
| Operating Income before D & A (EBITDA) | -6.04M | -4.00M | -7.25M | -10.86M |
| Depreciation & Amortization | 42.84K | 25.74K | 30.23K | 33.00K |
| Interest Income | 10.98K | 17.86K | 33.47K | 329.00K |
| Other Income - Net | -319.91K | 0.00 | 0.00 | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -6.39M | -4.01M | -7.24M | -10.56M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Pre-Tax Income | -6.39M | -4.01M | -7.24M | -10.56M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -6.39M | -4.01M | -7.24M | -10.56M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -6.39M | -4.01M | -7.24M | -10.56M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -6.39M | -4.01M | -7.24M | -10.56M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-6.39M | -4.01M | -7.24M | -10.56M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -6.39M | -4.01M | -7.24M | -10.56M |
| Basic EPS from Continuing Ops. | -0.29 | -0.22 | -0.48 | -0.81 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.29 | -0.22 | -0.48 | -0.81 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.29 | -0.22 | -0.48 | -0.81 |
| Basic Normalized Net Income/Share | -0.29 | -0.22 | -0.48 | -0.81 |
| EPS fr Continuing Ops. | -0.29 | -0.22 | -0.48 | -0.81 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.29 | -0.22 | -0.48 | -0.81 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.29 | -0.22 | -0.48 | -0.81 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.29 | -0.22 | -0.48 | -0.81 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with CPRX
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- UserSUPRATRADE EX-1006090013 DE...
- Userzhuangsn
- UserBRR Portfolio 1
- Userjaxplace Portfolio 1
- Usersovnek Portfolio 1
- UserDj Paul
- Userlouiis Portfolio 1
- Usercjthurman Portfolio 1
- Userajsny Portfolio 1
Latest CPRX Headlines from TheStreet
- 5 Stocks Setting Up to Break Out 12.20.11 | 01:12 pm
- Catalyst Announces Commencement Of CPP-109 Investigator-Sponsored Study In Cocaine And Alcohol Co-Dependent Patients 03.29.11 | 08:03 am
- Catalyst Pharmaceutical Partners To Present At The ROTH 23rd Annual OC Growth Stock Conference 03.09.11 | 11:03 am
- Catalyst Pharmaceutical Partners, Inc. Announces Public Offering Of Common Shares 03.08.11 | 09:03 am
- Catalyst Pharmaceutical Partners Promotes Steven R. Miller, Ph.D. To Chief Operating Officer 01.25.11 | 08:01 am
- Catalyst Pharmaceutical Partners To Present At The Biotech Showcase(TM) 2011 Conference 01.04.11 | 08:01 am
- Canadian Intellectual Property Office Grants Broad Patent For The Use Of Vigabatrin/CPP-109 For The Prevention Of Addiction In Pain Management 12.09.10 | 08:12 am
- Catalyst Pharmaceutical Partners Initiates A Registration-Directed U.S. Phase II(b) Clinical Trial In Collaboration With The National Institute On Drug Abuse And Veteran's Administration Cooperative Studies Program 11.18.10 | 08:11 am
- Catalyst Pharmaceutical Partners Announces Third Quarter 2010 Financial And Operational Results 11.16.10 | 08:11 am
- Dr. Richard B. Silverman Joins Catalyst Pharmaceutical Partners' Scientific Advisory Board 11.15.10 | 08:11 am
Press Releases for CPRX
- Vigabatrin/CPP-109 Data To Be Presented At College On Problems Of Drug Dependence Annual Meeting - PR Newswire 06.09.10 | 08:06 am
- Catalyst Pharmaceutical Partners To Present At The MoneyShow Conference - PR Newswire 05.07.10 | 08:05 am
- Catalyst Pharmaceutical Partners Regains Compliance With NASDAQ Minimum Bid Price Rule - PR Newswire 04.26.10 | 11:04 am
- Catalyst Pharmaceutical Partners Signs Definitive Agreement With The National Institute On Drug Abuse To Conduct U.S. Phase II(B) Clinical Trial For Cocaine Addiction - PR Newswire 04.13.10 | 10:04 am
- CPP-109 Clinical Trial Data To Be Presented At The American Society Of Addiction Medicine Annual Medical-Scientific Conference - PR Newswire 04.09.10 | 08:04 am
- Catalyst Pharmaceutical Partners Reports Fourth Quarter And Year-End 2009 Financial Results - PR Newswire 04.01.10 | 08:04 am
- Catalyst Pharmaceutical Partners To Present At The BioNetwork East 2010 Conference - PR Newswire 03.10.10 | 08:03 am
- Catalyst Pharmaceutical Partners To Present Today At 2010 Epilepsy Pipeline Update Conference - PR Newswire 02.25.10 | 08:02 am
- Catalyst Pharmaceutical Partners And The National Institute On Drug Abuse Plan To Initiate U.S. Phase II(b) Clinical Trial For Cocaine Addiction - PR Newswire 02.23.10 | 08:02 am
- Catalyst Pharmaceutical Partners Selected To Present At Epilepsy Conference Highlighting New And Promising Therapies - PR Newswire 02.17.10 | 08:02 am
Partner Headlines for CPRX
- Weekly CFO Buys Highlight: EMC, DVOX, NANX, CPRX, CCRN - GuruFocus 06.04.12 | 01:06 pm
- 7 Stocks Under $6 Poised To Double In 2012 - Seeking Alpha 11.24.11 | 06:11 am
- 6 Biotechs That Could See Huge Gains (Like Inhibitex) - Seeking Alpha 11.11.11 | 09:11 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 10.14.11 | 09:10 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 10.10.11 | 09:10 am
- Morning Market Losers - Benzinga 06.06.11 | 09:06 am
- 7 Big Movers That Investors Must Watch This Week - Seeking Alpha 06.06.11 | 08:06 am
- 7 Dirt-Cheap Takeover Targets in Biotech - Seeking Alpha 06.03.11 | 09:06 am
- Orphan Status for Catalyst Drug - Analyst Blog - Zacks 09.22.10 | 06:09 pm
- Biotech's Slow Week Gets Stirred by a Few Smaller Deals - Seeking Alpha 08.15.10 | 04:08 am
